The company has not filed an annual or quarterly report since its Q2 FY2019 10-Q, filed Jul 31, 2019. Its latest SEC filing is a SC 13G/A from Feb 16, 2021.
10-Q for Q2 FY2019, filed Jul 31, 2019
The sections below describe the company as of the FY2018 annual report.
Sells Algovita spinal cord stimulation systems for chronic pain to hospitals, surgery centers and medical facilities, and develops systems for bladder disorders and Parkinson’s disease.
10-K for FY2018, filed Mar 4, 2019Our Algovita® SCS system, or Algovita, is the first application of our neurostimulation technology platform and is indicated for the…View ↗
We have developed our existing platform for use in the SNM market and filed regulatory submissions with the FDA and CE Mark authorities in…View ↗
In addition, in early 2016, we entered into a development agreement with Aleva Neurotherapeutics S.A. (“Aleva”), which was amended and…View ↗
Algovita was designed to provide pain management solutions to patients who have evolving requirements and needs. We are still developing…View ↗
Customers pay for Algovita systems when the implantation procedure and required programming are complete, or when the system ships in sales without those services. Aleva pays a fixed monthly fee as development work progresses; royalties would be tied to Aleva’s later sales.
10-K for FY2018, filed Mar 4, 2019
$48.8M
10-K for FY2018, filed Mar 4, 2019
$48.8M ↗
Hospitals, surgery centers and medical facilities in the United States buy through Nuvectra’s direct sales force and third-party distributors; European buyers are reached through distributors. Aleva is the customer for the DBS development work.
10-K for FY2018, filed Mar 4, 2019Algovita was designed to provide pain management solutions to patients who have evolving requirements and needs. We are still developing…View ↗
In Europe, we currently have three distributors through which we sell Algovita. As we continue to develop our international sales…View ↗
Additionally, in the DBS market, our customer is Aleva, which we service through a strategic development agreement.View ↗
No. It lost $48.1M in FY2018.
10-K for FY2018, filed Mar 4, 2019
10-K for FY2018, filed Mar 4, 2019
−$43.2MView ↗
10-K for FY2018, filed Mar 4, 2019
−$48.1MView ↗
10-K for FY2018, filed Mar 4, 2019
−$39.4MView ↗
10-Q for Q2 FY2019, filed Jul 31, 2019
−$11.1MView ↗
8-K, filed Apr 20, 2020
On April 16, 2020, the Company filed a notice of continued hearing with the Bankruptcy Court setting a confirmation hearing with respect to…View ↗
8-K, filed Mar 25, 2020
The Company is permanently ending its operations. This decision is a result of the sale of the Company’s intellectual property and certain…View ↗
8-K, filed Jan 31, 2020
As previously disclosed, on November 12, 2019, Nuvectra Corporation (the “Company”) filed a voluntary petition for reorganization under…View ↗
8-K, filed Jan 15, 2020
In the Chapter 11 Case, the Company is conducting a sales process to sell the assets of the Company to one or more bidders under the…View ↗
Grew. Revenue grew 3.9x in 2 years, from $12.5M in FY2016 to $48.8M in FY2018, about 97% a year.
Loading...
